Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313456 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel
A Phase 1 study, sponsored by Agennix.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00313456: Clinical Trial Phase 1 study, sponsored by Agennix.
NCT00313456 is a Phase 1 study that was terminated before completion, run by Agennix. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00313456, a Phase 1 study, was terminated before completion, sponsored by Agennix.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a single-center, open-label (sequential-group dose-escalation dose-finding) phase I study of satraplatin and docetaxel in patients who have received prior chemotherapy regimens. Once the MTD is determined, an additional 6 patients, all with chemotherapy-naïve HRPC, will be enrolled. Once a recommended dose(s) (RD(s)) for phase 2 studies has/have been determined, 6 additional patients with chemotherapy-naïve HRPC will be enrolled at the RD to further evaluate safety and efficacy.
Interventions
- DRUG Satraplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-03 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Why NCT00313456 stopped before completion
NCT00313456 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which Satraplatin is the first listed.
NCT00313456 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00313456 about?
NCT00313456 is a clinical study titled "A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel". This is a single-center, open-label (sequential-group dose-escalation dose-finding) phase I study of satraplatin and docetaxel in patients who have received prior chemotherapy regimens. Once the MTD is determined, an additional 6 patients, all with chemotherapy-naïve HRPC, will be enrolled. Once a r...
What is the current status of trial NCT00313456?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2006-03. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00313456?
The interventions under investigation include: Satraplatin (DRUG).
Who is sponsoring clinical trial NCT00313456?
This trial is sponsored by Agennix, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00313456's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia